Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the ...
May 12 (Reuters) - Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC ...
Arvinas and Pfizer have chosen Rigel Pharmaceuticals to bring their recently approved breast-cancer drug Veppanu to market.
Arvinas (ARVN) stock is in focus as the company and Pfizer (PFE) sell global rights to their breast cancer drug, Verzenio, to ...
Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...
Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) jumped 20.9% in August, according to data provided by S&P Global Market Intelligence as investors in the biotech become more comfortable with the ...
(RTTNews) - Shares of Rigel Pharmaceuticals, Inc. (RIGL) are slipping over 11% in extended session on Monday after the company said it has received guidance from the U.S. Food and Drug ...
NEW YORK (AP) -- Shares of Rigel Therapeutics Inc. lost more than a third of their value Friday on mixed results from a late-stage clinical trial of a rheumatoid arthritis drug the company helped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results